cefuroxim. During subsequent days his condition deteriorated with severe sepsis and multiorgan failure. The leucocyte count decreased to 0.4 · 10 9 /l and the platelet count to 64 · 10 9 /l. Faecal cultures showed no pathogens. Blood cultures revealed growth of a bacillus species. An abdominal computed tomography scan showed signs of necrotising enterocolitis, and imipenem and granulocyte colony-stimulating factor were initiated. Despite recovery of the leucocyte count the patient died on the eighth day of admission. Autopsy revealed a denudated intestinal mucosa.
This case illustrates unexpected lethal toxicity on the oral 5-fluorouracil prodrug UFT. Severe intestinal and haematological toxicity of 5-FU is mostly related to deficiency of dihydropyrimidine dehydrogenase (DPD), an essential enzyme in the metabolic breakdown of 5-FU. In UFT, uracil is added to tegafur in order to bind DPD, resulting in a controlled DPD deficiency. Since capecitabine revealed no severe toxicity, apart from grade III hand-foot syndrome, it is very unlikely that DPD deficiency played a causative role in the severe UFT-related toxicity in this patient. Indeed, no polymorphisms in the DPYD gene were noted.
Since cytochrome P450 2A6 (CYP2A6) has been reported to metabolise tegafur to yield 5-FU [2] , a serum sample of the patient was screened for the polymorphisms CYP2A6*2, *3, *6, *9 and *12. The patient was heterozygous mutant for CYP2A6*9 (T-48G in the TATA box of the promoter) and wild type for the other polymorphisms. CYP2A6*9, with an allele frequency of 5% in Caucasians [3] , has been reported to reduce CYP2A6 activity (enzyme activity wild type > heterozygous mutant > homozygous mutant CYP2A6*9) [3, 4] . We therefore hypothesise that in this patient the metabolism of tegafur into 5-FU was decreased compared with patients with normal CYP2A6 activity. So tegafur may be alternatively metabolised by cytosolic enzymes resulting in increased toxicity.
Akay et al. [5] published a comparable case of severe gastrointestinal and haematological UFT toxicity, but tests to determine CYP2A6 polymorphisms had not been carried out. Unfortunately, no blood concentrations were measured of tegafur or 5-FU in both patients.
This case report is an example of lethal toxicity of UFT, probably due to altered metabolism of this 5-FU prodrug because of a CYP2A6 polymorphism. Physicians should be aware of unexpected severe toxicity of UFT in patients with CYP2A6 polymorphisms.
